Using a special laser-based 3D printing technique, researchers have produced micro-scaffolds with a diameter of less than a third of a millimetre, which can accommodate thousands of cells.
List view / Grid view
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
A newly developed blood vessel model can mimic the states of health and disease, paving the way for cardiovascular drug advancements.
Nanoengineers have developed a high-throughput bioprinter that 3D prints at record speed, potentially accelerating drug development.
A new study has shown that 3D printing can be used to control stem cell differentiation into embryoid bodies that replicate heart cells.
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
Researchers have developed a device which mimics how blinking and tear movement effect the cornea for use in testing ophthalmic drugs and ocular research.
A novel 4D printer has been created which can combine organic chemistry, surface science and nanolithography to design surfaces with organic or biological molecules for drug research.
A collapsible basket technology has been developed to significantly accelerate the analysis process when scientists are developing new medicines.
A new method has been created by researchers to 3D bioprint tumours and image glioblastomas for the study of therapeutics.
Scientists have shown an innovative new biomaterial made of graphene oxide and proteins could be used to 3D print model vascular structures.
A new imaging technique, which has revealed 3D forces exerted by tiny cell clusters, could help scientists understand how tissue forms, how wounds heal or how tumours spread.
Using modified hyaluronic acid and polyethylene glycol, researchers have created a bio-ink for 3D printing, which could be used as a scaffold to grow human tissues.
A new study into the enzyme Cdc34 may make it possible to target the enzyme specifically to develop new cancer therapeutics.